Key Takeaways SENS launched Eversense 365 with twiist, the first one-year implantable CGM integrated with an AID system.The SENS integration reduces sensor changes while enabling automated, real-time insulin dosing for users.SENS said first commercial patients are using the system, with broad availability expected by March 2026.Senseonics Holdings, Inc. (SENS) recently reached an important commercialization milestone with the launch of its Eversense 365 continuous glucose monitor (CGM) integrated with the t ...